Fig. 6.

Retreatment efficacies (mITT) in DAA-failure patients with rare GTs.

DAA, direct-acting antiviral; GT, genotype. mITT (modified intention-to-treat): retreated patients with completed follow-up visits. ^#One further patient started retreatment with VOX/VEL/SOF for 12 weeks and was lost during the on-treatment visits. Thus, the overall TT SVR rate was 92% (45/49) and the VOX/VEL/SOF ITT SVR rate was 93% (27/29). Further 11 patients were not retreated, of whom 8 patients were lost and further 3 patients died due to HCC. ∗n = 4 patients with HCV GT1/GT4 subtypes unassigned.